Table 2.
Multivariate analysis of survival by lymph node ratio and pN stage
|
Characteristic |
LRFS |
OS |
||
|---|---|---|---|---|
| HR (95% CI) | p | HR (95% CI) | p | |
| Age (y) |
|
|
|
|
| ≤ 35 vs. > 35 |
1.664 (1.082-2.558) |
0.020* |
— |
|
| Menopausal status |
|
|
|
|
| Pre- vs. postmenopausal |
1.623 (1.106-2.383) |
0.105 |
— |
|
| Tumor size |
|
|
|
|
| T3-4 vs. T1-2 |
1.636 (1.029-2.600) |
0.037 |
1.392 (0.917-2.113) |
0.121 |
| ER status |
|
|
|
|
| Negative vs. positive |
1.536 (1.095-2.155) |
0.013* |
1.054 (0.699-1.590) |
0.802 |
| PR status |
|
|
|
|
| Negative vs. positive |
1.626 (1.148-2.302) |
0.317 |
1.490 (1.040-2.136) |
0.030* |
| HER-2-neu status |
|
|
|
|
| Positive vs. negative |
— |
|
1.208 (0.888-1.644) |
0.228 |
| Hormone therapy |
|
|
|
|
| None vs. yes |
1.180 (0.731-1.904) |
0.498 |
1.570(1.093-2.255) |
0.015* |
| Lymph node ratio |
|
|
|
|
| < 0.20 |
1 (Reference) |
|
1 (Reference) |
|
| 0.21-0.65 |
1.886 (1.273-2.794) |
0.002* |
1.964 (1.387-2.782) |
<0.001* |
| > 0.65 |
5.013 (3.191-7.877) |
<0.001* |
7.381 (5.161-10.557) |
<0.001* |
| Number of positive lymph nodes |
|
|
|
|
| pN1 |
1 (Reference) |
|
|
|
| pN2 |
0.828 (0.476-1.442) |
0.522 |
1.327 (0.808-2.179) |
0.263 |
| pN3 | 0.894 (0.437-1.828) | 0.907 | 1.654 (0.904-3.027) | 0.103 |
LRFS, Locoregional recurrence-free survival; OS, Overall survival; ER, Estrogen receptor; PR, Progesterone receptor; Her-2, Human epithelial growth factor receptor family 2; HR, Hazard ratio; CI, Confidence interval.
*p<0.05 indicates a significant difference.